In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Neos Therapeutics (NEOS), with a price target of $20. The company’s shares opened today at $3.04.
Chen commented:
“. We hosted two days of meetings with NEO’s CEO Jerry McLaughlin and CFO Richard Eisenstadt. The takeaways from these meetings underscore our OW rating and 12-month PT of $20 for NEOS stock. These meetings increased our confidence that NEOS’s restructuring plan to optimize value over volume in ADHD, and expand its pipeline are both underappreciated. Therefore, continued success with the sales of its key ADHD drugs (Adzenys ER), as well as pipeline advancements (NT-0400 and NT-0502), should drive upwards earnings revisions to levels not reflected in the consensus and move NEOS’s stock higher.”
According to TipRanks.com, Chen is a 5-star analyst with an average return of 12.9% and a 45.6% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Amneal Pharmaceuticals Inc.
Currently, the analyst consensus on Neos Therapeutics is a Moderate Buy with an average price target of $20.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.70 and a one-year low of $1.40. Currently, Neos Therapeutics has an average volume of 370.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company’s extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX.
